Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Research by the DNA Damage & Disease research group has for the first time observed molecular fibres that may hold together sections of broken DNA in mitosis.

DNA breaks are a significant source of errors and mutations that can lead to cancer. Cells possess DNA repair systems that try to correct these errors, although sometimes the repair process itself can create cancerous mutations. Understanding how DNA repair functions, or mis-functions in cancer, is therefore an important area of research. The DNA Damage & Disease research group at the MRC WIMM is one of several research groups in Oxford tackling this issue.

Early markers of DNA repair

DNA repair mechanisms are known to be active in interphase, the part of the cell cycle when the cell is not actively dividing. It is currently believed that no DNA repair takes place in mitosis. However, cells can at least detect DNA breaks during mitosis, as early players in the DNA repair process are still recruited to DNA damage. But is this early recruitment of DNA repair players important for cells to survive DNA breaks in mitosis? Does it act as a flag to mark breaks that must be repaired later, or is it just the signs of an incomplete repair process?

To address this question, the DNA Damage & Disease research group and their collaborators in the Stucki lab at the University of Zurich examined cells lacking the last known DNA repair protein to be recruited to the DNA breaks in mitosis, the scaffolding protein MDC1. Specifically, they asked whether cells lacking MDC1 were able to cope when exposed to ionising radiation, which causes DNA breaks. The researchers showed that these cells were less able to survive DNA breaks in mitosis than their MDC1-containing counterparts, suggesting that MDC1 is indeed important for cell survival during cell division.

Molecular fibres

As MDC1 is known to be a scaffolding protein, the next question was to determine what other proteins it recruits to the DNA breaks. In conjunction with collaborators at the University of Oxford’s Target Discovery Institute, the team used mass spectrometry to identify an evolutionarily conserved player called TopBP1 as a binding partner for MDC1. With the help of the MRC WIMM’s Wolfson Imaging Facility, the team was then able to image TopBP1 at high resolution. What they observed was surprising:

Most known DNA repair players are visible on DNA as very localised dots (foci), recruited to the precise areas where the DNA is broken” explains Dr Andrew Blackford, senior author on this study. “Our imaging shows that TopBP1 localises to DNA by forming filaments that bridge MDC1 foci, which, we hypothesise, may be holding together two sections of broken DNA. This process must be regulated by the cell in some way during mitosis, as we never observe these fibres in interphase”.

The team is now interested in understanding whether any other DNA repair proteins localise to these fibres, how the process is regulated and how it plays a role in DNA repair in mitosis. They also hope to explore whether this might be a new therapeutic target for cancer treatment.


Dr Andrew Blackford is a Group Leader in the Department of Oncology and the MRC Oxford Institute for Radiation Oncology.

Similar stories

Scientists find genetic ‘marker’ linked to serious side-effects from skin cancer treatment

New research from the Fairfax Group has identified a genetic marker that could be used to predict a patient’s risk of developing serious side-effects when undergoing immunotherapy treatment for metastatic melanoma.

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the city’s two National Institute for Health and Care Research (NIHR) Biomedical Research Centres (BRC).

The Department represented at the European Radiation Research Society annual conference

Researchers from the Department of Oncology attend the prestigious European Radiation Research Society (ERRS) in annual conference in Catania, Italy to present their research in Radiation Oncology.

Funding to research metformin’s ability to delay or prevent cancers driven by the mutated TP53 gene

A research project embedded within the Metformin in Li Fraumeni (MILI) trial will investigate metformin’s mechanism of action when taken as a preventative for mTP53-driven cancers.

Cancer patients remain at higher risk of severe COVID-19 disease despite third dose booster vaccine

A large population-level assessment reveals third dose COVID-19 vaccination is effective for most patients with cancer, but effectiveness is lower than in the general population, particularly in patients who have undergone recent chemotherapy and those with lymphoma.

Time-varying nature of clinical risk factors for pancreatic cancer may aid earlier diagnosis

Body mass index, blood tests, comorbidities and medication use are temporally associated with cancer risk in the three years before a pancreatic cancer diagnosis.